Vita Spring provided the funding as QuantuMDx also pursues commercialisation discussions with Sansure Biotech.
"I am very pleased to announce this equity investment today which will enable us to further evolve the Q-POC™ platform, making our system one of the most innovative, high multiplexing, molecular point of care devices in the market. Vita Spring shares our mission of developing accurate and efficient solutions to identify pathogens and diagnose diseases and so we are delighted they have chosen to invest in QuantuMDx. We are also looking forward to our close future relationship with Sansure and believe they will be an excellent partner for QuantuMDx in China as we look to increase our global footprint in Chinese and adjacent markets."
— Jonathan O’Halloran, Co-founder and Chief Executive
The Series A round was led by Maven VC and Guinness Asset Management to support post-pandemic healthcare recovery.
"As we continue to accelerate and invest in the ethical use of clinical research data to advance new medicines for patient care, this funding gives us the capital needed to carry out our immediate plans while delivering AI solutions which will help futureproof our NHS."
Hambro Perks led the seed investment, which will fund team expansion and market growth.
"At the UN’s COP26 summit, world leaders, CEOs and celebrities will announce promises to address the climate crisis. But how hollow are these promises? Corporates, investors and governments are accused of greenwashing and will likely fall short of their commitments. A large part of this is due to a lack of accurate, validated and transparent data."
Mercia backed the seed round to support product development and commercial growth.
"We’re on a mission to help businesses transform their data from an expensive, time-consuming challenge into a powerful goal-achieving asset. In Mercia we have found the perfect partner to expand our product and accelerate the growth for Distil and its customers."
